Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC) - Wikidata - wikimedia - TriplyDB

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)

http://www.wikidata.org/entity/Q28284519

about

Predictive biomarkers for treatment selection: statistical considerations Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling Strategies for power calculations in predictive biomarker studies in survival data Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo.Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics.Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis.Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer Endostar enhances the antitumor effects of radiation by affecting energy metabolism and alleviating the tumor microenvironment in a Lewis lung carcinoma mouse model 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations DACH1 inhibits the proliferation and invasion of lung adenocarcinoma through the downregulation of peroxiredoxin 3.SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma.miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Icotinib: activity and clinical application in Chinese patients with lung cancer.Involvement of nuclear protein C23 in activation of EGFR signaling in cervical cancer.MiR-129 regulates MMP9 to control metastasis of non-small cell lung cancer.Epidermal growth factor induces FoxO1 nuclear exclusion to activate MMP7-mediated metastasis of larynx carcinoma.MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer.Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer.Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.New multi-component solid forms of anti-cancer drug Erlotinib: role of auxiliary interactions in determining a preferred conformation.Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas.Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer.[Advances in immunotherapies for non-small cell lung cancer].

P2860

Q26778367-0199F46A-DC18-4919-8FC8-0F74EDCB44E0 Q26781643-BF7CFA56-8621-468A-975C-242D63095A8E Q31132692-B3FADC7C-E99B-44D6-A0FF-87C5781A7545 Q33700689-B218056E-8589-4A7E-852D-5F5D79379831 Q33888789-111E6C73-C465-4C70-AAA1-EBD1089C98B9 Q34028492-2E8C0DB4-422F-44C7-8022-D8A4D9AB6A86 Q34092436-1BF44BE3-B203-4686-B578-504DE8A9E782 Q34404209-76EA0132-29C2-4F8C-A93D-A1106D937FA0 Q34430551-D47D5A57-F732-4EEC-B28C-9736024C60FE Q34996125-8D2DA379-611A-465D-AEED-D9D1ADC4AC71 Q35267340-24FF9595-20C1-4973-90EE-C52D5458145F Q35879427-349D4E99-954B-4869-A3A9-E948B85A5202 Q36063291-9C85B73D-EFBC-4A81-9E9E-20AEDB2E73A9 Q36183714-D56C4221-5078-4519-9E36-946B0C3A2E79 Q36335475-9F79AA5A-DB7E-499F-B52F-8190D41FED01 Q36688956-9DC42AD4-545A-4ACD-87DC-D632A2B254AC Q37013280-9F1C8B21-9DE2-46B8-B4B6-076633DFBB7A Q37188174-C2598DD7-14E8-41C3-B8DF-1F51F2D611D1 Q37457747-0EE5349F-1BEE-45A8-9D92-5BD432ECD812 Q37564535-EC8DBFCA-2569-4F84-98F5-5E93A2ADBF3F Q37698439-8E2BEA58-6227-416A-8EBD-912C3DD38566 Q38192719-4297F98E-BE93-4FF8-BCBC-334966654A2A Q38845264-B1774950-3FF3-43B8-8E75-C9357F557AD9 Q38906016-5CF65FA1-F214-4EBF-9B7E-960FD5535361 Q38976850-911BAB46-899D-4AC4-B7DB-95A1728456A1 Q39007269-DF98BB2B-E589-4CAC-8BC2-2CB1DBA3148B Q42290027-946D2E2B-F522-4518-ABC1-794589EF37BE Q42290335-FE0BF226-B708-419A-B410-B61AE3E1C4F8 Q47957249-B34AF491-3849-41E2-BCDC-1783B07B89D1 Q51311873-6B78696A-EC95-4287-A49A-618C270531DE Q52903547-C5A64888-3A6B-4035-9585-997D6A04DA8C Q55028849-8E2AE8A2-2BB9-4565-9FA7-06386573BFA2 Q55177170-D23981D5-473B-458A-BE13-577000E62CC7 Q55441788-A5DF4E32-C9EB-4CCD-A7FF-410AB0FCA1D6

P2860

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)

http://www.wikidata.org/entity/Q28284519

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@ast

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@en

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@nl

type

label

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@ast

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@en

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@nl

prefLabel

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@ast

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@en

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@nl

P1433

Q28284519-A7EB5549-AAD8-4FA4-8C97-5691161AA440

P1476

Q28284519-84755782-360B-4739-88FE-DEB2E131E8DE

P2093

Q28284519-2CA3C269-B15B-4BE7-BAA3-A469B10195A8

Q28284519-5590F893-F1C9-4E75-883E-0B0D547738F6

P2860

Q28284519-004CAFCE-77CA-4212-B228-B03164A95C7A

Q28284519-077D64BF-A129-4D4B-A751-E3FC74208475

Q28284519-0FE78E2F-0F7B-4C6F-9A76-CB5A9CA4F892

Q28284519-107899C8-C6E8-43E3-8A02-8353D3B28164

Q28284519-17800CA3-74A0-40A2-8BF0-48AAD9A9EB43

Q28284519-24FE8990-6ADE-48F1-9430-21950048CC00

Q28284519-2D6D6874-EB62-4DA4-9B7C-ABDA5E3DC5FA

Q28284519-359A533F-890E-4495-9AEB-2E05D2096D17

Q28284519-408D8938-522F-451A-82CE-6FF915A8D21D

Q28284519-40E49129-F5A5-4013-9948-1F605C3F0546

P2888

Q28284519-3932224E-410A-4744-B265-E9FB43D68C56

P304

Q28284519-DD70813A-7ACD-4CE0-9294-24E7678BA111

P31

Q28284519-705156A3-9D34-49C6-878C-ADFBFF78FCEC

Q28284519-EB88382E-84C0-4668-A3EF-C60A4C2C94C3

P3181

Q28284519-C42E29BF-1F01-43D7-8319-46B74AE4F481

P356

Q28284519-E0C0E70E-7C98-4F0B-A95F-A7463425D3A4

P407

Q28284519-402A4774-2861-4130-9CF4-2097AA88F5E7

P433

Q28284519-F3CBBE20-558C-4FF7-8489-991575E0BBA5

P478

Q28284519-5AEF8579-40C5-44B0-A7A7-B7947247488A

P577

Q28284519-4DC96829-3621-430C-98D7-CD62A980F3B6

Q28284519-9FFA7024-BA2B-4628-80D8-53821DFC1057

P5875

Q28284519-5DE2A487-B7F3-4BFA-BE95-431DDC66F4AF

P6179

Q28284519-4A8F6CEC-DC3B-4EC1-8A08-5F82C175F7AA

P698

Q28284519-7D511335-507A-4937-AF30-E8DB93634841

P921

Q28284519-29C0881B-F3C4-4FDD-B9BA-167A085E8FC5

Q28284519-92FB5AF0-BF65-42DD-ACC4-A8911E190E39

Q28284519-969FF40C-C942-4950-890B-3427366E89C4

Q28284519-9BB75FED-E809-4E3C-B0A0-6C68B834495E

Q28284519-AF50EC62-2543-4858-B7B4-90DF54C8EAA4

Q28284519-B8B501AD-A747-4BA4-A276-2B13C012C2C7

Q28284519-BD8DCD65-E2F7-4359-966E-8B96AC91FA6A

Q28284519-E170EC70-C48A-4610-AF4C-64AAE656BB10

P932

Q28284519-6D480072-A056-4D58-895C-0DCFD93CA07A

P3181

P356

S11523-013-0258-9

P1433

Targeted oncology

P1476

Epidermal growth factor recept ...... small cell lung cancer (NSCLC)

@en

P2093

Koichi Hagiwara

http://www.w3.org/2001/XMLSchema#string

Kunihiko Kobayashi

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Screening for epidermal growth factor receptor mutations in lung cancer

P2888

s11523-013-0258-9

P304

27-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

455544

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11523-013-0258-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235382711

http://www.w3.org/2001/XMLSchema#string

P6179

1009759282

http://www.w3.org/2001/XMLSchema#string

P698

23361373

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

mechanism of action

genetic variation

non-small-cell lung carcinoma

membrane proteins

P932

3591525

http://www.w3.org/2001/XMLSchema#string